Avidity of Antibodies to Cytomegalovirus in HIV-Seropositive Patients with and without CMV Retinitis

Viral Immunology

Volumn 17, Issue 1, 2004, Pages 101-108

  Marshall, Beth C ^a   Jacobson, Mark A ^b   Adler, Stuart P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ELECTROIMMUNOASSAY; FEMALE; FETUS RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RETINITIS; SEROLOGY; VIRUS IMMUNITY; VIRUS PATHOGENESIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 1542513299     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282404322875494     Document Type: Article

References (21)

1. Alberola, J., V. Domininquez, L. Cardenoso, et al. 1998. Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. J. Med. Virol. 55:272-280.
2. Alberola, J., A. Tamarit, and D. Navarro. 1999. Functional antibody response to human cytomegalovirus in immunocompetent and HIV-1-infected individuals with antibodies that inhibit virus penetration into cells and intercellular transmission of viral infection. J. Med. Microbiol. 48:947-954.
3. Alberola, J., A. Tamarit, L. Cardenoso, et al. 2001. Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. J. Med. Virol. 64:35-41.
4. Baril, L., M. Jouan, R. Agher, et al. 2000. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 14:2593-2596.
5. Blackburn, N.K., T.G. Besselaar, B.D. Schoub, et al. 1991. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J. Med. Virol. 33:6-9.
6. Boppana, S.B., M.A. Polis, A.A. Kramer, et al. 1995. Virus-specific antibody responses to human cytomegalovirus in human immunodeficiency virus type 1-infected persons wth HCMV retinitis. J. Infect. Dis. 171:182-185.
7. Boppana, S.B., and W.J. Britt. 1995. Antiviral antibody responses and intrauterine transmission after primary cytomegalovirus infection. J. Infect. Dis. 171:1115-1121.
8. + patients with haemophilia: titre and avidity. Clin. Exp. Immunol. 93:331-336.
9. Chargelegue, D., C.M. Stanley, C.M. O'Toole, et al. 1995. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin. Exp. Immunol. 99:175-181.
10. Jonjic, S., I. Pavic, B. Polic, et al. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179:1713-1717.
11. + T-lymphocyte responses after gancyclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med. 4:953-956.
12. + lymphocytes. AIDS 8:469-476.
13. + T-lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect. Dis. 21:1197-1203.
14. Kroon, F.P., M.J. van Tol, C.M. Jol-van der Zijde, et al. 1999. Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin. Diagn. Lab. Immunol. 6:352-355.
15. Lutch, E., V.A. Sundqvist, A. Linde, et al. 1994. Presence of autologous neutralizing antibodies against cytomegalovirus (CMV) in serum of human immunodeficiency virus type 1-infected patients shedding CMV in saliva. J. Infect. Dis. 169:1096-1100.
16. Macdonald, R.A., C.S. Hosking, and C.L. Jones. 1988. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 106:191-194.
17. Rasmussen, L., S. Morris, R. Wolitz, et al. 1994. Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J. Infect. Dis. 170:673-677.
18. Thomas, H.I., S. Wilson, C.M. O'Toole, et al. 1996. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin. Exp. Immunol. 103:185-191.
19. Thomas, H.I., and H.C. Aird. 1999. Maintenance of high-avidity rubella-specific IgG antibody and titres in recent HIV seroconverters and in patients progressing to the AIDS-related complex and AIDS. J. Med. Virol. 58:273-279.
20. Varani, S., P. Spezzacatena, R. Manfredi, et al. 2000. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur. J. Epidemiol. 16:433-437.
21. Walter, E.A., P.D. Greenberg, M.J. Gilbert, et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.